Media Archives

• November 2004

  Sequella, Inc., and Sankyo Co., Ltd. Sign Worldwide Licensing Agreement to Develop and Market Promising New Anti-Tuberculosis Compounds (pdf)

• February 2002

  Dr. Carol Nacy of Sequella, Inc. Named As One of Fast Company Magazine's Fast 50 Champions of Innovation (pdf)

• January 2002

  Sequella, Inc. Announces Positive Late Stage Clinical Trial Results for a Revolutionary TB Diagnostic (pdf)

• October 2001

  Springboard: New England 2001 Selects Sequella, Inc. to Present at November Venture Forum for Women Entrepreneurs (pdf)

• June 2001

  Sequella, Inc. Receives NCI/NIAID Inter-Institute Program Scientific Support for the Development of Novel Second-Generation Drugs for Tuberculosis (pdf)

• April 2001

  Sequella, Inc. Receives NIH Grant to Develop Tuberculosis Diagnostic Device (pdf)

For further information, please contact:

Sequella, Inc.
9610 Medical Center Drive, Suite 200
Rockville, MD 20850
Telephone: 301-762-7776